Navigation Links
Gene variation increases SIDS risk in African Americans

About five percent of deaths from SIDS (sudden infant death syndrome) in African Americans can be traced to defects in one gene and half of those deaths result from a common genetic variation that increases an infant's risk of developing an abnormal heart rhythm during times of environmental stress, a research team based at the University of Chicago reports in the February 2006 issue of the Journal of Clinical Investigation.

Children with two copies of the common genetic variation have a 24-fold increased risk of sudden death as infants. One out of nine African Americans carries one copy of the common variant. One copy does not appear to increase risk for infants.

"The common polymorphism alone does not cause SIDS," said Steven Goldstein, M.D., Ph.D., professor and chairman of pediatrics at the University of Chicago and director of the study. "Our findings suggest, however, that it renders infants vulnerable to environmental challenges -- such as a long pause in respiration -- that are tolerated by children without the mutation."

"The hope," he added, "is that findings like this may one day allow us to intervene. We might screen to identify children at high risk and teach parents how to lessen the likelihood of secondary challenges. We have already begun to evaluate drugs that may mitigate the risk."

SIDS -- the sudden and unanticipated death of an infant with no detectable lethal disorder -- is the leading cause of infant deaths in the United States, representing nearly one-third of deaths between one month and one year of age. African Americans have three times greater risk of SIDS than Caucasians and six times the risk of Hispanics or Asians, suggesting an important role for genetics.

The researchers studied the genes in tissue collected from 133 African-American infants with a diagnosis of SIDS after autopsy. They compared results with tissue samples from 1,056 African-American adults with no known health problems.
'"/>

Source:University of Chicago Medical Center


Page: 1 2 3

Related biology news :

1. Gene variations explain drug dose required to control seizures
2. Survival of heart patients on beta-blockers varies greatly with genetic variation
3. Genetic variation alters response to common anti-clotting drug
4. Studies on human genome variation provide insight into disease
5. Gene variation affects tamoxifens benefit for breast cancer
6. New discovery: Molecular variation in one gene affects the growth of natural populations
7. Researchers map of genetic variations implicated in disease
8. Chimpanzee study reveals genome variation hotspots
9. A new kind of mutation could explain numerous phenotypic variations in various species
10. International team analyzes human genetic variation in key immune region
11. New technology used to construct the first map of structural variation in the human genome

Post Your Comments:
(Date:11/25/2009)...ach, may be used to boost resistance to, or slow, ...l of Medicine researchers report in a study publis...nce . , Parkinson,s disease is caused by a degen...rain known as the substantia nigra, which is respo...n of dopamine in late-stage Parkinson,s causes sym...
(Date:11/25/2009)...eath Research Laboratory in the University of Haif...estigious Johnson & Johnson Focused Funding grant ... damage in Parkinson,s disease. The award, which i...novation and excellence in science, was announced ...th at an event at the Hyatt Regency Hotel in New J...
(Date:11/25/2009)...fessors recently received funding from the Nationa...neficial to understanding the environment. The thr...d, assistant professor in the Department of Biolog...eparate research projects. , His first project, ...nd Functions from the Leaf to the Landscape," will...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Rigel to Present at Jefferies Healthcare Conference 48415 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 1Oramed Pharmaceuticals to Present at the 8th National Life Science 26 Technology Week ILSI BIOMED Conference Israel 2009 4583 2
... subjects to operate a robot-controlled joystick, ...er the brain "learns" to control certain muscle mo...son over the long haul. The results, the investiga...r people who have lost motor abilities to brain in... the May 23 issue of PLoS Biology, the researchers...
...archers have found a group of cells in the intesti...lls, cells that help fight infection. , The resear...journal Immunity, released today. , "This connect... will help in studying and developing treatments f...m," said Stephen McSorley, Ph.D., professor of med...
...t four factors, researchers have successfully indu...or adult mice to behave like embryonic stem cells....ediate early publication of the journal Cell, publ...rchers designate "induced pluripotent stem cells" ...haracteristics typical of embryonic stem cells, th...
Other Biology News:New approach to vaccine development provides potent, long-lasting immunity 2New approach to vaccine development provides potent, long-lasting immunity 3With few factors, adult cells take on character of embryonic stem cells 2
(Date:11/24/2009)..., REDWOODCITY,Calif.,Nov.24/PRNewswire-FirstCal...dthatRandyScott,GenomicHealth,sExecutiveChairman,w...ferenceinNewYorkCityonTuesday,December1,2009at10:0...vedwebcastofthepresentation,visittheInvestorRelati...or.genomichealth.com .Pleaseconnecttothewebsiteatl...
(Date:11/24/2009)... Chemical Abstracts Service ...reports that China,s patent office is now the worl...ons in chemistry. China trailed Japan,s patent off...(WIPO), and the United States Patent and Trademark... the USPTO in 2005, WIPO in 2006, and exceeded Jap...
(Date:11/23/2009)...HAMPAIGN, Ill. You can think of it as origami ve...sity of Illinois have developed a technique for fa...licon structures from thin films by coupling photo...apillary interactions. , The films, only a few mi...not possible with thicker pieces of the same mater...
(Date:11/23/2009)..., INCLINEVILLAGE,Nev.,Nov.23/PRNewswire-FirstCa...ouncedthatNASDAQhasestablishedNovember27,2009asthe...tockholdersresultingfromthesecuritizationtransacti...nDecember15,2009toallstockholdersofrecordonthereco...rshareamountofthedividendat$1.67pershareofcommonst...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Water droplets direct self-assembly process in thin-film materials 2PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2
...., Jan. 13 Nektar Therapeutics,(Nasdaq: NKTR ) ... 2 clinical,trial of NKTR-102 in platinum-resistan...been obtained and dosing will begin shortly in two...evaluate NKTR-102 versus irinotecan in,second-line...ation, and a,Phase 2 study in metastatic breast ca...
.... 13 Burnham Institute for Medical Research (Burn...greement with Johnson & Johnson Pharmaceutical...he agreement is Burnham,s first broad-based partne...der this multi-year agreement, Burnham will provid...screening technologies to investigate certain drug...
...., Jan. 13 Neurobiological,Technologies, Inc. (Na...owing a,detailed analysis of the recent interim re...any has decided not to develop Viprinex further fo... was recently studied in a,clinical trial to deter...,outcome when given within six hours of a stroke, ...
Other Biology Technology:First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 2First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 3First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer 4Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2Neurobiological Technologies Announces Suspension of Viprinex Development 2Neurobiological Technologies Announces Suspension of Viprinex Development 3
Mouse Anti-Mouse Qa-2 Monoclonal Antibody, Alexa Fluor 647 Conjugated, Clone 695H1-9-9 from BioLegend
27-mer duplex from B-Bridge International
Propidium Iodide Buffer from BioLegend
Luminex 100 Instrument System from Upstate
Biology Products: